porcine antihuman lymphocyte immunoglobulin

Porcine antihuman lymphocyte immunoglobulin (pATG or pALG) is a porcine-derived polyclonal antithymocyte globulin (ATG) preparation used as an immunosuppressive agent. It is produced by immunizing healthy pigs with human-derived thymocytes or peripheral lymphocytes, followed by purification of the porcine IgG fraction. pATG acts by binding to a wide range of T-cell surface antigens, leading to T-lymphocyte depletion via complement-dependent cytolysis and antibody-dependent cell-mediated cytotoxicity, as well as the inhibition of T-cell activation and proliferation. It is primarily approved and used in China for the treatment of severe aplastic anemia (SAA) and as induction therapy or graft-versus-host disease (GvHD) prophylaxis in hematopoietic stem cell and solid organ transplantation.

Brand names

p-ALG

Other names

ATG-Panti-human T lymphocyte porcine immunoglobulinantihuman T lymphocyte porcine immunoglobulinp-ATGpALGpATGporcine anti-human lymphocyte immunoglobulinporcine antilymphocyte globulinporcine antilymphocyte serum抗人T细胞猪免疫球蛋白猪抗人T细胞免疫球蛋白猪抗人淋巴细胞免疫球蛋白猪抗人淋巴细胞球蛋白